Mortality due to non‑AIDS‑defining cancers among people living with HIV in Spain over 18 years of follow‑up
Loading...
Identifiers
Publication date
Authors
Suárez-García, Inés
Gutiérrez, Félix
Pérez Molina, José A.
Moreno, Santiago
Aldamiz Echevarría, Teresa
Advisors
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Purpose Our aim was to describe non-AIDS-defining cancer (NADC) mortality among people living with HIV (PLWH),
to compare it with that of the general population, and to assess potential risk factors.
Methods We included antiretroviral-naive PLWH from the multicentre CoRIS cohort (2004–2021). We estimated mortality
rates and standardised mortality ratios (SMRs). We used cause-specific Cox models to identify risk factors.
Results Among 17,978 PLWH, NADC caused 21% of all deaths observed during the follow-up. Mortality rate due to NADC
was 1.58 (95%CI 1.36, 1.83) × 1000 person-years and lung and liver were the most frequent cancer-related causes of death.
PLWH had 79% excess NADC mortality risk compared to the general population with the highest SMR found for Hodgkin
lymphoma, anal and liver cancers. The SMRs decreased with age and were the highest in age groups under 50 years. The
most important prognostic factor was low CD4 count, followed by smoking, viral hepatitis and HIV transmission through
heterosexual contact or injection drug use.
Conclusion Non-AIDS cancers are an important cause of death among PLWH. The excess mortality related to certain
malignancies and the association with immunodeficiency, smoking, and coinfections highlights the need for early detection
and treatment of cancer in this population.
Description
UNESCO Subjects
Keywords
Bibliographic reference
Suárez-García, I., Gutierrez, F., Pérez-Molina, J. A., Moreno, S., Aldamiz, T., Valencia Ortega, E., Curran, A., Gutiérrez González, S., Asensi, V., Amador Prous, C., Jarrin, I., Rava, M., & CoRIS. (2023). Mortality due to non-AIDS-defining cancers among people living with HIV in Spain over 18 years of follow-up. Journal of Cancer Research and Clinical Oncology, 149(20), 18161-18171. https://doi.org/10.1007/s00432-023-05500-9


